Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Overview | 12 | 1 |
| Therapeutics Development | 13 | 5 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Products under Development by Stage of Development | 13 | 1 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Products under Development by Therapy Area | 14 | 1 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Products under Development by Indication | 15 | 3 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Pipeline Products Glance | 18 | 2 |
| Late Stage Products | 18 | 1 |
| Early Stage Products | 19 | 1 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Products under Development by Companies | 20 | 9 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Products under Development by Universities/Institutes | 29 | 2 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Therapeutics Assessment | 31 | 6 |
| Assessment by Monotherapy/Combination Products | 31 | 1 |
| Assessment by Mechanism of Action | 32 | 1 |
| Assessment by Route of Administration | 33 | 2 |
| Assessment by Molecule Type | 35 | 2 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Companies Involved in Therapeutics Development | 37 | 27 |
| Abeome Corporation | 37 | 1 |
| Alnylam Pharmaceuticals, Inc. | 38 | 1 |
| AlphaMab Co., Ltd | 39 | 1 |
| AstraZeneca Plc | 40 | 1 |
| Aurigene Discovery Technologies Limited | 41 | 1 |
| BeiGene, Ltd. | 42 | 1 |
| Bristol-Myers Squibb Company | 43 | 1 |
| CytomX Therapeutics, Inc. | 44 | 1 |
| Eli Lilly and Company | 45 | 1 |
| F. Hoffmann-La Roche Ltd. | 46 | 1 |
| Genosco | 47 | 1 |
| ImmunoCellular Therapeutics, Ltd. | 48 | 1 |
| Immunocore Limited | 49 | 1 |
| IO Biotech ApS | 50 | 1 |
| Kadmon Corporation, LLC | 51 | 1 |
| MedImmune, LLC | 52 | 2 |
| Merck KGaA | 54 | 1 |
| Novartis AG | 55 | 1 |
| PsiOxus Therapeutics Limited | 56 | 1 |
| Regeneron Pharmaceuticals, Inc. | 57 | 1 |
| Shanghai Henlius Biotech Co., Ltd. | 58 | 1 |
| Sorrento Therapeutics, Inc. | 59 | 1 |
| Sutro Biopharma, Inc. | 60 | 1 |
| Theravectys SA | 61 | 1 |
| Tikcro Technologies, Ltd. | 62 | 1 |
| ViiV Healthcare Limited | 63 | 1 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Drug Profiles | 64 | 75 |
| ALN-PDL Drug Profile | 64 | 1 |
| Antibody to Inhibit PD-L1 for Oncology Drug Profile | 65 | 1 |
| atezolizumab Drug Profile | 66 | 11 |
| AUPM-327 Drug Profile | 77 | 1 |
| avelumab Drug Profile | 78 | 5 |
| Biologic to Inhibit PD-L1 for Immunology Drug Profile | 83 | 1 |
| BMS-936559 Drug Profile | 84 | 3 |
| CA-170 Drug Profile | 87 | 2 |
| CBA-0710 Drug Profile | 89 | 1 |
| CX-072 Drug Profile | 90 | 1 |
| dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide Drug Profile | 91 | 1 |
| durvalumab Drug Profile | 92 | 9 |
| durvalumab + gefitinib Drug Profile | 101 | 1 |
| durvalumab + IMCgp-100 + tremelimumab Drug Profile | 102 | 1 |
| durvalumab + MEDI-0680 Drug Profile | 103 | 1 |
| durvalumab + MEDI-6383 Drug Profile | 104 | 1 |
| durvalumab + MEDI-9447 Drug Profile | 105 | 1 |
| durvalumab + monalizumab Drug Profile | 106 | 1 |
| durvalumab + tremelimumab Drug Profile | 107 | 3 |
| GNS-1480 Drug Profile | 110 | 1 |
| HLX-10 Drug Profile | 111 | 1 |
| HLX-20 Drug Profile | 112 | 1 |
| IO-103 Drug Profile | 113 | 1 |
| KD-033 Drug Profile | 114 | 1 |
| KN-035 Drug Profile | 115 | 1 |
| LY-3300054 Drug Profile | 116 | 1 |
| Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections Drug Profile | 117 | 1 |
| Monoclonal Antibodies to Inhibit PD-L1 for Oncology Drug Profile | 118 | 1 |
| Monoclonal Antibodies to Inhibit PDL1 for Oncology Drug Profile | 119 | 1 |
| Monoclonal Antibodies to Inhibit PDL1 for Oncology Drug Profile | 120 | 1 |
| Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors Drug Profile | 121 | 1 |
| Monoclonal Antibody to Inhibit PD-L1 for Oncology Drug Profile | 122 | 1 |
| Monoclonal Antibody to Inhibit PD-L1 for Oncology Drug Profile | 123 | 1 |
| Monoclonal Antibody to Inhibit PD-L1 for Oncology Drug Profile | 124 | 1 |
| Monoclonal Antibody to Inhibit PDL-1 for Influenza Drug Profile | 125 | 1 |
| Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology Drug Profile | 126 | 1 |
| MSB-002 Drug Profile | 127 | 1 |
| Oncolytic Viruses to Inhibit PDL1 for Solid Tumors Drug Profile | 128 | 1 |
| Small Molecules to Inhibit PD-L1 and PD-L2 for Oncology Drug Profile | 129 | 1 |
| STIA-1011 Drug Profile | 130 | 1 |
| STIA-1012 Drug Profile | 131 | 1 |
| STIA-1014 Drug Profile | 132 | 1 |
| STIA-1015 Drug Profile | 133 | 1 |
| Synthetic Peptide 1 to Inhibit PD-L1 for Oncology Drug Profile | 134 | 1 |
| Synthetic Peptide 2 to Inhibit PDL1 for Oncology Drug Profile | 135 | 1 |
| Vaccine to Target CD274 and CD279 for Bladder Cancer Drug Profile | 136 | 1 |
| Vaccine to Target CD274 and CD279 for Colorectal Cancer Drug Profile | 137 | 1 |
| Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma Drug Profile | 138 | 1 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Dormant Projects | 139 | 1 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Discontinued Products | 140 | 1 |
| Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Featured News &Press Releases | 141 | 16 |
| Jun 06, 2016: ASCO 2016: Pivotal Avelumab Study Shows Positive Results In Metastatic Merkel Cell Carcinoma | 141 | 1 |
| Jun 05, 2016: New Drug "Retrains" Immune System to Fight Aggressive Bladder Cancer | 142 | 1 |
| Jun 05, 2016: Roche's cancer immunotherapy Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer | 143 | 2 |
| Jun 05, 2016: Durvalumab Monotherapy Demonstrates Efficacy in Urothelial Bladder Cancer | 145 | 1 |
| Jun 01, 2016: Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints | 145 | 1 |
| May 19, 2016: Aurora Diagnostics to Offer PD-L1 Tissue Assay for TECENTRIQ (atezolizumab) | 146 | 1 |
| May 19, 2016: New Complementary Diagnostic Test Available from LabCorp for Treatment of Bladder Cancer | 147 | 1 |
| May 18, 2016: FDA Grants Genentech s Cancer Immunotherapy TECENTRIQ (atezolizumab) Accelerated Approval for People with a Specific Type of Advanced Bladder Cancer | 147 | 1 |
| May 18, 2016: Merck And Pfizer To Present Avelumab Data In Seven Different Cancers At ASCO Annual Meeting | 148 | 3 |
| Apr 14, 2016: Kadmon to Present Preclinical Data Demonstrating that its Novel Immuno-Oncology Compound Achieves Long-Lasting and Persistent Antitumor Immunity | 151 | 1 |
| Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-170 and PD-L1/TIM-3 Antagonist at AACR Annual Meeting | 151 | 1 |
| Apr 10, 2016: FDA Grants Priority Review for Genentech s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer | 152 | 1 |
| Apr 06, 2016: Ludwig Cancer Research And The Cancer Research Institute Initiate Clinical Trial Of A Novel Combination Immunotherapy For Ovarian Cancer | 153 | 1 |
| Apr 05, 2016: Merck And Pfizer Announce First Patient Treated In Phase III Combination Study With Avelumab And INLYTA In Renal Cell Carcinoma | 154 | 1 |
| Mar 15, 2016: Experimental Targeted Immunotherapy Drug Performs Better Than Chemotherapy for Treatment of Advanced Lung Cancer | 155 | 2 |
| Appendix | 157 | 2 |
| Methodology | 157 | 1 |
| Coverage | 157 | 1 |
| Secondary Research | 157 | 1 |
| Primary Research | 157 | 1 |
| Expert Panel Validation | 157 | 1 |
| Contact Us | 157 | 1 |
| Disclaimer | 158 | 1 |